[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eurosets S.r.l.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":86},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":35,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100620224","safety-and-performance-evaluation-of-cpb-venous-and-arterial-cannulas-100620224",false,"NCT07354841","Safety and Performance Evaluation of CPB Venous and Arterial Cannulas","A Two Phases Clinical Investigation Consisting of a Pre-Market, Pilot, Interventional, Not Randomized, Monocentric Investigation to Evaluate the Safety of PVC Arterial Cannula and PVC Venous Cannula (Class III Medical Devices) Intended to be Used During Cardiopulmonary Bypass (CPB) Procedure Followed by a Pre-Market, Pivotal, Interventional, Randomized, Non- Inferiority, Monocentric Investigation to Confirm the Safety and Evaluate the Performance of the Same Cannulas","Inclusion Criteria:\n\n1. Patient is considered able and willing to provide written informed consent according to the ethically approved informed consent form;\n2. Female and male patients aged ≥ 18;\n3. Body weight between 60 and 120 kg;\n4. Body surface area (BSA) between 1.5 and 2.5 m2;\n5. Patients scheduled to undergo central cannulation for cardiopulmonary bypass (CPB) in elective surgery procedures (isolated coronary and\u002For aortic valve surgery).\n\nExclusion Criteria:\n\n1. Emergency cases;\n2. Re-do cardiac surgery procedure;\n3. Diabetes mellitus;\n4. Hematologic diseases or history of thrombophilia;\n5. Pregnancy or breastfeeding;\n6. Concomitant major cardiac procedures;\n7. Active malignant\u002Fmetastatic neoplasm of any type;\n8. Presence of pneumothorax and\u002For pulmonary emphysema;\n9. Significant central nervous system injury;\n10. Current intracranial hemorrhage;\n11. Immunosuppression;\n12. Contraindication for therapeutic anticoagulation (e.g., heparin);\n13. Anatomical and structural abnormalities which, in the opinion of the Investigator, may interfere with the participation to the study;\n14. Abnormal or pathological cannulation site;\n15. Uncontrolled active bleeding;\n16. Awaiting transplantation;\n17. Requiring preoperative extracorporeal membrane oxygenation;\n18. Presence of any relevant severe condition or clinically relevant abnormal laboratory parameters that in the opinion of the Investigator may interfere with the participation to the study.\n19. Patient is taking part in another interventional clinical study;\n20. Patient is not able to understand the nature of this study or is unwilling or unable to attend the EOS Visit.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a two-phase study evaluating the Eurosets arterial and venous cannulas for use during cardiopulmonary bypass (CPB) procedures. Phase 1 is a pilot study focused on assessing cannula safety. Phase 2 is a pivotal study aimed at confirming safety and evaluating efficacy through comparison with Medtronic cannulas (control group).\n\nThe results will be compared for non-inferiority with those obtained using the control group cannulas.",[26,27,28,29,30,31,32,33,34],"Cardiac Surgery","Heart Surgery","Cardiopulmonary Bypass","Coronary Surgery","Aortic Valve Surgery","Cannulation","Venous Cannulation","Arterial Cannulation","Coronary Surgery With Cardiopulmonary Bypass",[36,37,38,28,26,39,40,41,30,29,42,43,44,45,46,47,48,49],"Arterial Cannula","Venous Cannula","Extracorporeal Circulation","Medical Device","Device Safety","Device Performance","Two Phases clinical investigation","Monocentric Study","Two Phases Study","Serious Adverse Events (SAE)","CVP","NIRS","Venous Cannula Drainage Pressure","Arterial Cannula Reinfusion Pressure","RECRUITING","2026-01-12",{"date":53,"type":54},"2026-01-21","ACTUAL",{"date":56,"type":54},"2025-10-21",{"date":58,"type":20},"2026-09-30",{"name":60,"class":61},"Eurosets S.r.l.","INDUSTRY",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":62},"100451855","eurosets-ecmo-study-in-clinical-extracorporeal-life-support-applications-100451855","NCT05163925","EUROSETS ECMO Study in Clinical Extracorporeal Life Support Applications","A Prospective Single Center Study to Evaluate Safety and Efficacy of the EUROSETS Extracorporeal Membrane Oxygenation ECMOLIFE SYSTEM in Clinical Extracorporeal Life Support Applications EUROSETS ECMO STUDY","Inclusion Criteria:\n\n* Patients ≥18 years\n* VA-ECLS application using the EUROSETS ECMOLIFE SYSTEM (e.g. cardiogenic shock, post cardiotomy low cardiac output syndrome, cardiac arrest, high risk percutaneous coronary intervention, eCPR)\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* Pregnant and breastfeeding women",{"count":71,"type":20},30,"OBSERVATIONAL","This is a prospective single-center study designed for evaluation of safety and performance of the Conformitè Europëenne (CE)-marked EUROSETS ECMOLIFE SYSTEM, composed by: ECMOLIFE console, ECMO TUBING SET, ECMO OXYGENATOR and ECMOLIFE CENTRIFUGAL PUMP, HEATER COOLER (called ECMOLIFE HC) in all clinical ECLS applications (e.g. post-cardiotomy ECLS as well as application for cardiogenic shock after myocardial infarction or resulting from other etiologies, as well as ECLS application in patients under cardiopulmonary resuscitation (eCPR) and protected PCI) in 30 consecutive patients.\n\nAll demographic and perioperative variables (ECMOLIFE SYSTEM -related and unrelated ECLS complications, performances of the ECMOLIFE SYSTEM) will be analyzed. Surgical techniques will be recorded. Follow-up information on survival and any adverse cardiac and cerebrovascular events will be gathered routinely by outpatient clinic and telephone calls until 30 days after ECLS initiation or hospital discharge.",[75],"Extracorporeal Membrane Oxygenation Complication",[77],"Extracorporeal Life Support Applications","2025-07-01",{"date":80,"type":54},"2025-07-02",{"date":82,"type":54},"2022-01-10",{"date":84,"type":20},"2025-07",{"name":60,"class":61},""]